J D Baxter1, D Dunn2, A Tostevin2, R L Marvig3, M Bennedbaek4, A Cozzi-Lepri2, S Sharma5, M J Kozal6, M Gompels7, A N Pinto8, J Lundgren4. 1. Cooper University Hospital/Cooper Medical School of Rowan University, Camden, NJ, USA. 2. Institute for Global Health, UCL, London, UK. 3. Center for Genomic Medicine, Copenhagen University Hospital, Rigshospitalet, Denmark. 4. Copenhagen HIV Programme, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 5. Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA. 6. Yale University School of Medicine, New Haven, CT, USA. 7. North Bristol NHS Trust, Westbury on Trym, UK. 8. The Kirby Institute, University of New South Wales, Sydney, Australia.
Abstract
OBJECTIVES: The aim of this analysis was to characterize transmitted drug resistance (TDR) in Strategic Timing of Antiretroviral Treatment (START) study participants by next-generation sequencing (NGS), a sensitive assay capable of detecting low-frequency variants. METHODS: Stored plasma from participants with entry HIV RNA > 1000 copies/mL were analysed by NGS (Illumina MiSeq). TDR was based on the WHO 2009 surveillance definition with the addition of reverse transcriptase (RT) mutations T215N and E138K, and integrase strand transfer inhibitor (INSTI) surveillance mutations (Stanford HIVdb). Drug resistance mutations (DRMs) detected at three thresholds are reported: > 2%, 5% and 20% of the viral population. RESULTS: Between 2009 and 2013, START enrolled 4684 antiretroviral therapy (ART)-naïve individuals in 35 countries. Baseline NGS data at study entry were available for 2902 participants. Overall prevalence rates of TDR using a detection threshold of 2%/5%/20% were 9.2%/5.6%/3.2% for nucleoside reverse transcriptase inhibitors (NRTIs), 9.2%/6.6%/4.9% for non-NRTIs, 11.4%/5.5%/2.4% for protease inhibitors (PIs) and 3.5%/1.6%/0.1% for INSTI DRMs and varied by geographic region. Using the 2% detection threshold, individual DRMs with the highest prevalence were: PI M46IL (5.5%), RT K103NS (3.5%), RT G190ASE (3.1%), T215ISCDVEN (2.5%), RT M41L (2.2%), RT K219QENR (1.7%) and PI D30N (1.6%). INSTI DRMs were detected almost exclusively below the 20% detection threshold, most commonly Y143H (0.4%), Q148R (0.4%) and T66I (0.4%). CONCLUSIONS: Use of NGS in this study population resulted in the detection of a large proportion of low-level variants which would not have been detected by traditional Sanger sequencing. Global surveillance studies utilizing NGS should provide a more comprehensive assessment of TDR prevalence in different regions of the world.
OBJECTIVES: The aim of this analysis was to characterize transmitted drug resistance (TDR) in Strategic Timing of Antiretroviral Treatment (START) study participants by next-generation sequencing (NGS), a sensitive assay capable of detecting low-frequency variants. METHODS: Stored plasma from participants with entry HIV RNA > 1000 copies/mL were analysed by NGS (Illumina MiSeq). TDR was based on the WHO 2009 surveillance definition with the addition of reverse transcriptase (RT) mutations T215N and E138K, and integrase strand transfer inhibitor (INSTI) surveillance mutations (Stanford HIVdb). Drug resistance mutations (DRMs) detected at three thresholds are reported: > 2%, 5% and 20% of the viral population. RESULTS: Between 2009 and 2013, START enrolled 4684 antiretroviral therapy (ART)-naïve individuals in 35 countries. Baseline NGS data at study entry were available for 2902 participants. Overall prevalence rates of TDR using a detection threshold of 2%/5%/20% were 9.2%/5.6%/3.2% for nucleoside reverse transcriptase inhibitors (NRTIs), 9.2%/6.6%/4.9% for non-NRTIs, 11.4%/5.5%/2.4% for protease inhibitors (PIs) and 3.5%/1.6%/0.1% for INSTI DRMs and varied by geographic region. Using the 2% detection threshold, individual DRMs with the highest prevalence were: PI M46IL (5.5%), RT K103NS (3.5%), RT G190ASE (3.1%), T215ISCDVEN (2.5%), RT M41L (2.2%), RT K219QENR (1.7%) and PI D30N (1.6%). INSTI DRMs were detected almost exclusively below the 20% detection threshold, most commonly Y143H (0.4%), Q148R (0.4%) and T66I (0.4%). CONCLUSIONS: Use of NGS in this study population resulted in the detection of a large proportion of low-level variants which would not have been detected by traditional Sanger sequencing. Global surveillance studies utilizing NGS should provide a more comprehensive assessment of TDR prevalence in different regions of the world.
Authors: Birgitte B Simen; Jan Fredrik Simons; Katherine Huppler Hullsiek; Richard M Novak; Rodger D Macarthur; John D Baxter; Chunli Huang; Christine Lubeski; Gregory S Turenchalk; Michael S Braverman; Brian Desany; Jonathan M Rothberg; Michael Egholm; Michael J Kozal Journal: J Infect Dis Date: 2009-03-01 Impact factor: 5.226
Authors: Karin J Metzner; Alexandra U Scherrer; Benjamin Preiswerk; Beda Joos; Viktor von Wyl; Christine Leemann; Philip Rieder; Dominique Braun; Christina Grube; Herbert Kuster; Jürg Böni; Sabine Yerly; Thomas Klimkait; Vincent Aubert; Hansjakob Furrer; Manuel Battegay; Pietro L Vernazza; Matthias Cavassini; Alexandra Calmy; Enos Bernasconi; Rainer Weber; Huldrych F Günthard Journal: J Infect Dis Date: 2013-07-11 Impact factor: 5.226
Authors: Elizabeth L Yanik; Sonia Napravnik; Christopher B Hurt; Ann Dennis; E Byrd Quinlivan; Joe Sebastian; Joann D Kuruc; Joseph J Eron Journal: J Acquir Immune Defic Syndr Date: 2012-10-01 Impact factor: 3.731
Authors: Shaili Gupta; Max Lataillade; Tassos C Kyriakides; Jennifer Chiarella; Elizabeth P St John; Suzin Webb; Elizabeth A Moreno; Birgitte B Simen; Michael J Kozal Journal: Viruses Date: 2014-09-16 Impact factor: 5.048
Authors: Huldrych F Günthard; Vincent Calvez; Roger Paredes; Deenan Pillay; Robert W Shafer; Annemarie M Wensing; Donna M Jacobsen; Douglas D Richman Journal: Clin Infect Dis Date: 2019-01-07 Impact factor: 9.079
Authors: Jeffrey A Johnson; Jin-Fen Li; Xierong Wei; Jonathan Lipscomb; David Irlbeck; Charles Craig; Amanda Smith; Diane E Bennett; Michael Monsour; Paul Sandstrom; E Randall Lanier; Walid Heneine Journal: PLoS Med Date: 2008-07-29 Impact factor: 11.069
Authors: Michelle L D'Antoni; Kristen Andreatta; Rima Acosta; Hal Martin; Silvia Chang; Ross Martin; Kirsten L White Journal: J Acquir Immune Defic Syndr Date: 2022-04-01 Impact factor: 3.771
Authors: Yang Li; Leilei Han; Yanglan Wang; Xiaolin Wang; Lei Jia; Jingyun Li; Jingwan Han; Jin Zhao; Hanping Li; Lin Li Journal: Front Microbiol Date: 2022-08-22 Impact factor: 6.064